###begin article-title 0
Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease
###end article-title 0
###begin p 1
Recommended by Mostafa Badr
###end p 1
###begin p 2
###xml 89 94 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 96 101 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 237 242 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 491 496 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 662 663 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 691 692 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 723 724 719 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1114 1115 1110 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1218 1219 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1301 1302 1297 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1331 1336 1327 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 363 366 <span type="species:ncbi:9606">men</span>
###xml 407 410 <span type="species:ncbi:9606">men</span>
###xml 414 419 <span type="species:ncbi:9606">women</span>
###xml 1268 1271 <span type="species:ncbi:9606">men</span>
###xml 1401 1404 <span type="species:ncbi:9606">men</span>
Single nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptor gamma (PPARG) gene have been associated with cardiovascular risk factors, particularly obesity and diabetes. We assessed the relationship between 4 PPARG SNPs (C-681G, C-689T, Pro12Ala, and C1431T) and coronary heart disease (CHD) in the PRIME (249 cases/494 controls, only men) and ADVANCE (1,076 cases/805 controls, men or women) studies. In PRIME, homozygote individuals for the minor allele of the PPARG C-689T, Pro12Ala, and C1431T SNPs tended to have a higher risk of CHD than homozygote individuals for the frequent allele (adjusted OR [95% CI] = 3.43 [0.96-12.27], P = .058, 3.41 [0.95-12.22], P = .060 and 5.10 [0.99-26.37], P = .050, resp.). No such association could be detected in ADVANCE. Haplotype distributions were similar in cases and control in both studies. A meta-analysis on the Pro12Ala SNP, based on our data and 11 other published association studies (6,898 CHD cases/11,287 controls), revealed that there was no evidence for a significant association under the dominant model (OR = 0.99 [0.92-1.07], P = .82). However, there was a borderline association under the recessive model (OR = 1.29 [0.99-1.67], P = .06) that became significant when considering men only (OR = 1.73 [1.20-2.48], P = .003). In conclusion, the PPARG Ala12Ala genotype might be associated with a higher CHD risk in men but further confirmation studies are needed.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 47 52 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 231 232 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 483 484 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 581 582 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
The peroxisome proliferator-activated receptor gamma (PPARG) is a nuclear hormone receptor that dimerizes with the retinoid X receptor (RXR) to regulate target genes involved in adipocyte differentiation and insulin sensitization [1]. Activation of PPARG with thiazolidinediones is used to stimulate insulin sensitivity in the treatment of type 2 diabetes. PPARG also plays a role in macrophage, malignant breast epithelial, colon cancer cell differentiation, and lipid homeostasis [2] and has been shown to control the expression of proinflammatory genes in vascular cell models [3]. This suggests that PPARG may contribute to the pathogenesis of the atherosclerotic plaque physiology at a very early stage.
###end p 4
###begin p 5
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG </italic>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 717 725 <span type="species:ncbi:9606">patients</span>
Prior investigations have analyzed the relationship between common PPARG SNPs and various metabolic disorders. The Pro12Ala substitution in the specific exon B of PPARG2 isoform, which contributes to a lower PPARG2 activity in vitro, was associated with a decreased risk of type 2 diabetes [4]. Obese carriers of the minor allele of the PPARG C1431T polymorphism in exon 6 presented higher plasma leptin levels than noncarriers [5]. The C-681G and C-689T polymorphisms in the second and third PPARG promoter, respectively, were both associated with higher body weight and plasma LDL concentrations [6, 7]. Finally, haplotype analyses showed that a particular combination of these 4 polymorphisms was more frequent in patients with a metabolic syndrome than in control subjects [8]. Altogether, these observations suggest that genetic variability at the PPARG locus could affect cardiovascular risk.
###end p 5
###begin p 6
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 416 421 416 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 646 651 646 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 838 843 838 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Early studies analyzed the association between the PPARG Pro12Ala SNP and coronary heart disease (CHD) in cohorts from North America. These investigations yielded inconsistent results [9, 10]. Furthermore, a higher risk of coronary heart disease was reported in obese subjects carrying the Ala12 allele that needed confirmation [10]. Therefore, the goal of the present study was to explore the association between 4 PPARG SNPs, including the Pro12Ala SNP, and CHD risk in two independent studies among white subjects. We also performed haplotype analyses to evaluate whether a particular combination of alleles could better explain the effect of PPARG genetic variability on CHD risk and assessed whether overweight and obesity could modulate this risk. Finally, we performed a meta-analysis of published studies to date, focusing on the PPARG Pro12Ala polymorphism and CHD risk.
###end p 6
###begin title 7
2. Methods
###end title 7
###begin title 8
2.1. PRIME Study
###end title 8
###begin p 9
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 433 434 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 280 283 <span type="species:ncbi:9606">men</span>
The PRIME (Prospective Study of Myocardial Infarction) study is a prospective cohort study designed to identify risk factors for CHD [11]. Details on recruitment, baseline examination, and follow-up of the PRIME Study have been previously reported [12]. Overall, 9758 middle-aged men aged 50-59 years and free of CHD at baseline were recruited in Lille, Strasbourg, and Toulouse in France (n = 7399) and Belfast in Northern Ireland (n = 2359) between 1991 and 1993 and followed up for 5 years for the occurrence of first CHD events including coronary death, nonfatal myocardial infarction, and stable or unstable angina pectoris.
###end p 9
###begin title 10
2.1.1. General Characteristics
###end title 10
###begin p 11
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 785 786 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 805 806 801 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 459 466 <span type="species:ncbi:4097">tobacco</span>
Subjects who agreed to take part in the study were given a morning appointment and asked to fast for at least 12 hours. A full description of clinical and laboratory measurements has been published elsewhere [11, 12]. Briefly, a health questionnaire self-administered by subjects at their homes was subsequently checked by trained interviewers at the clinic. It covered a broad range of clinical information, including family and personal clinical histories, tobacco consumption, and drug intake. Blood pressure was measured twice in the sitting position with the same automatic device (Spengler SP9). A 12-lead ECG was also recorded. Plasma lipids analyses were centralized (SERLIA INSERM U325, Institut Pasteur de Lille, France). Overweight and obesity were defined as BMI >/=25 kg/m2 and BMI >/=30 kg/m2, respectively.
###end p 11
###begin title 12
2.1.2. Biochemical Measurements
###end title 12
###begin p 13
A subset of biochemical measurements was performed on the entire cohort at baseline. Total cholesterol and triglycerides were measured by enzymatic methods using commercial kits in an automatic analyzer (Boehringer, Mannheim, Germany). High-density lipoprotein (HDL) cholesterol was determined after precipitation of Apo-lipoprotein B by an enzymatic method (Boehringer). Low-density lipoprotein (LDL) cholesterol was calculated according to the Friedewald formula. Insulin was assayed by competitive radioimmunoassay (Sanofi-Diagnostic Pasteur, France) in cases and matched controls using plasma samples collected at baseline and stored in liquid nitrogen.
###end p 13
###begin p 14
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 956 968 <span type="species:ncbi:9606">participants</span>
###xml 1001 1013 <span type="species:ncbi:9606">participants</span>
During the follow-up, subjects were contacted annually by letter and asked to complete a clinical event questionnaire. For all subjects reporting a possible event, clinical information was sought directly from the hospital or general practitioner records. All details on ECGs, hospital admissions, enzymes, surgical intervention, angioplasty, treatments, and so forth were collected. Death certificates were checked for supporting clinical and postmortem information on cause of death. Whenever possible, circumstances of death were obtained from the practitioner or the family. A Medical Committee comprising one member from each PRIME Center and the Coordinating Center, and three cardiologists (two from France and one from the UK), was established to provide an independent validation of coronary events. A description of the coronary end point definitions has been published recently [12]. The five-year follow-up was completed in 98,6% of the French participants and 99,2% of the Northern-Irish participants.
###end p 14
###begin p 15
###xml 129 141 <span type="species:ncbi:9606">participants</span>
###xml 298 310 <span type="species:ncbi:9606">participants</span>
A nested case-control study within the PRIME prospective cohort study was mounted using the baseline plasma samples of 335 study participants who subsequently developed a future coronary ischemic event during follow-up and of 670 matched controls (2 controls per case). Matched controls were study participants recruited in the same center, on the same day (+/-3 days), of the same age (+/-3 years) as the case and free of CHD at the time of the ischemic event of the case. Subjects with incomplete data were excluded. If a case was excluded, his two matched controls were also excluded, and if the two matched controls for a case were excluded, the corresponding case was also excluded. A total of 249 cases and 494 controls were used in the present study.
###end p 15
###begin title 16
2.2. The ADVANCE Study
###end title 16
###begin p 17
###xml 1048 1050 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1246 1248 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1250 1252 1246 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 963 975 <span type="species:ncbi:9606">participants</span>
###xml 1589 1592 <span type="species:ncbi:9606">men</span>
###xml 1601 1606 <span type="species:ncbi:9606">women</span>
The Atherosclerotic Disease, VAscular FuNction, and genetiC Epidemiology (ADVANCE) study recruited, between October 2001 and December 2003, a total of 3,179 subjects from multiple race/ethnic background into 5 cohorts: a cohort of subjects with clinically significant CAD at a young age (</=45 years for males, </=55 years for females), a cohort of subjects with incident stable angina at an older age, a cohort of subjects with incident acute myocardial infarction (AMI) at an older age, a cohort of young subjects with no history of CAD, and a cohort of subjects aged 60 to 72 with no history of CAD, ischemic stroke, or peripheral arterial disease (PAD). Eligible subjects were identified using the Kaiser Permanente of Northern California (KPNC) electronic databases and those who agreed to participate were interviewed and examined at one of several clinics in the San Francisco Bay Area. A sixth cohort of young subjects with no history of CAD included 479 participants in the Coronary Artery Risk Development in Young Adults (CARDIA) Study [13] originally recruited through KPNC and attending the study's year 15 examination cycle in 2000-2001. A detailed description of the source population for all cohorts has been published elsewhere [14, 15]. The design of the ADVANCE study allowed for several case control comparisons. In this study, we included all white subjects with symptomatic early onset CAD (young cases), older subjects with either AMI or angina as first presentation of CHD (older cases), young controls, and older controls. This resulted in 1 076 CHD cases (706 in men, 370 in women) and 805 controls (433 male, 372 female).
###end p 17
###begin p 18
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
The ADVANCE study was approved by the Institutional Review Board at both Stanford University and Kaiser Permanente of Northern California (KPNC). Details of the methodology for risk factor assessment can be found elsewhere [14, 15].
###end p 18
###begin title 19
2.3. Genotyping
###end title 19
###begin p 20
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 174 179 <span type="species:ncbi:9606">Human</span>
The genotyping method in PRIME has been described previously [8]. The genotyping success rate was above 94% for each SNP. Genotyping in ADVANCE was performed at the Stanford Human Genome Center using the ABI 7900 TaqMan platform [16, 17]. The "no call rate" for genotypes was only 0.35% and the reproducibility was 99.9% in random samples with repeat genotypes.
###end p 20
###begin title 21
2.4. Statistical Analyses
###end title 21
###begin p 22
For ADVANCE, we used unconditional logistic regression because cases and controls were not individually matched. For PRIME, we used conditional logistic regression analysis to compare the distribution of genotypes between cases and controls and to estimate the odds ratio (OR) of CHD. The analyses were adjusted for age, educational level, alcohol consumption, physical activity, smoking status, history of diabetes, history of hypertension, and history of dyslipidemia. Additional analyses were performed to test the interaction between overweight or obesity and genotype by adding a cross-product term to the logistic regression model. We used general regression models and chi-square test to compare the clinical and biological characteristics of the subjects according to genotype in control subjects. Triglyceride values were log transformed for analyses. All analyses were performed using SAS software 8.2 version (SAS Institute, Cary, USA).
###end p 22
###begin title 23
2.4.1. Haplotype Analyses
###end title 23
###begin p 24
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 191 194 191 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 201 204 201 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">min</sub>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
Presence of linkage disequilibrium between the loci was tested using a log-likelihood-ratio test [18] and the degree of disequilibrium was expressed in terms of normalized difference D' = D/Dmax or D/Dmin [19]. Haplotype frequencies were estimated using a stochastic version of the expectation-maximization algorithm as implemented in Thesias software [20, 21]. Differences in haplotype frequencies between cases and their respective controls were examined using a log-likelihood ratio statistic test which was computed from the estimated haplotype frequency log-likelihoods for the case and control groups separately.
###end p 24
###begin title 25
2.4.2. Meta-Analysis
###end title 25
###begin p 26
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1275 1277 1275 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1472 1479 1472 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
In addition to the analysis of PRIME and ADVANCE, we identified all published prospective studies that assessed the relationship between the PPARG Pro12Ala polymorphism and CHD and conducted a meta-analysis of the findings. Inclusion criteria for events were a coronary event. Inclusion criteria for exposure variable were the PPARG Pro12Ala polymorphism. Searches were conducted in electronic databases (MEDLINE and EMBASE) from 1970 to June 2009. References from the extracted papers, reviews, and previous meta-analysis were also consulted to complete the data bank. The electronic search include both truncated free-text and MeSH. Used terms were "PPARG" or "peroxisome proliferator-activated receptor gamma" and "polymorphism" and "cardiovascular disease" or "CAD" or "CHD" or "coronary" or "MI" or "myocardial" or "ischemic heart disease." No attempt was made to contact authors of nonpublished work or to find paper in other languages than English. When the data were not available in the appropriate format, the corresponding author of the paper was contacted to obtain the data. However, two studies were excluded because the data were not available in the appropriate format, that is, the number of subjects for the three genotype groups in cases and controls [22, 23]. Finally, 11 studies were selected for the meta-analysis. Therefore, the final data set, including our 3 samples, consisted of 14 independent studies comprising 6898 cases and 11 287 controls (Table 4).
###end p 26
###begin p 27
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
For this meta-analysis, we combined data of all studies using Review Manager software release 5.0 () [24]. We estimated the overall effect by a Mantel-Haentzel fixed odds ratio.
###end p 27
###begin title 28
3. Results
###end title 28
###begin p 29
###xml 255 262 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
As expected, major cardiovascular risk factors such as smoking, history of hypertension, history of dyslipidemia, history of diabetes, and systolic and diastolic blood pressure levels differed between cases and controls in both PRIME and ADVANCE studies (Table 1).
###end p 29
###begin p 30
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 352 353 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 403 413 403 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2(a)</xref>
The genotype distributions of the 4 PPARG SNPs respected the Hardy-Weinberg equilibrium in control subjects. In the control group, the frequencies of the PPARG -681G, -689T, Ala12, and 1431T alleles were similar in PRIME and ADVANCE. There were marginal differences in the genotype distribution of the C-689T (P = .04), Pro12Ala (P = .03), and C1431T (P = .04) SNPs between cases and controls in PRIME (Table 2(a)), mainly due to a higher frequency of homozygote subjects for the minor allele in cases compared with controls.
###end p 30
###begin p 31
###xml 193 203 193 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2(a)</xref>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 429 430 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 463 464 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 500 501 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 749 750 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 778 779 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 810 811 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 947 957 947 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2(b)</xref>
###xml 962 965 962 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">(c)</xref>
###xml 1020 1021 1020 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1039 1040 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1062 1063 1060 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1081 1082 1077 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1170 1171 1166 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 929 932 <span type="species:ncbi:9606">men</span>
###xml 940 945 <span type="species:ncbi:9606">women</span>
The odds ratios (ORs) [95% CI] of CHD were calculated for heterozygotes, for homozygotes, and for carriers of the minor allele (dominant model), using both a crude model and an adjusted model (Table 2(a)). In PRIME, homozygote individuals for the minor allele of the PPARG C-689T, Pro12Ala, and C1431T SNPs tended to have a higher risk of CHD than homozygote individuals for the frequent allele (OR [95% CI] = 3.34 [0.98-11.45], P = .054, OR = 3.32 [0.97-11.39], P = .056 and OR = 5.93 [1.19-29.45], P = .029, resp.). After adjustment for age, educational level, smoking status, physical activity, alcohol intake, history of diabetes, history of hypertension, and history of dyslipidemia, the ORs were only slightly altered (OR = 3.43 [0.96-12.27], P = .058, 3.41 [0.95-12.22], P = .060 and 5.10 [0.99-26.37], P = .050 for the C-689T, Pro12Ala and C1431T SNPs, resp.). There was no significant association in ADVANCE, neither in men nor in women (Table 2(b) and (c)). Further analyses stratifying on overweight (<25 kg/m2 versus >/=25 kg/m2) or obesity (<30 kg/m2 versus >/=30 kg/m2) or adding a cross-product term into the model yielded no significant interaction (all P values for interaction term >0.1) in both studies (data not shown).
###end p 31
###begin p 32
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 350 351 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> PPARG</italic>
In control subjects from PRIME and ADVANCE, there were very few significant differences in baseline characteristics between carriers and noncarriers of the PPARG-681G, -689T, Ala12, and 1431T alleles (see Tables 1, 2, 3, 4, and 5 in Supplementary Material available online at doi:10.155/2009/543746). Systolic blood pressure was significantly lower (P < .05) in carriers of the PPARG-681G, -689T and Ala12 alleles in PRIME (Supplementary Table 1). There was no statistically significant difference in mean BMI, LDL-cholesterol, or HDL-cholesterol levels between carriers and noncarriers of the minor allele of any SNP investigated. There was also no evidence for any statistically significant difference in the prevalence of reported hypertension, dyslipidemia, or diabetes between carriers and noncarriers of the minor allele of these SNPs.
###end p 32
###begin p 33
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 104 106 104 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8201;&#8201;</italic>
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8201;&#8201;</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 333 340 333 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 660 661 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The Pro12Ala and the C-681G, C-689T, and C1431T SNPs were in partial positive linkage disequilibrium (D'  range = +0.6 - +1.0, r2  range = 0.18-0.98). The C-689T and Pro12Ala SNPs were in perfect linkage disequilibrium (D' = +1.0, r2 = 0.98). The distribution of the 4 SNP -containing haplotypes was estimated in cases and controls (Table 3). Six haplotypes covered 98% of the possible haplotypes. The frequency of the haplotype composed of the 4 most frequent alleles was >70% in both cases and controls. There was no evidence for any statistically significant difference in haplotype distribution between cases and controls, neither in PRIME nor in ADVANCE (P > .38). Haplotype analyses were also conducted after stratification on overweight or obesity. In these analyses, there was no evidence of significant difference of haplotype distributions between cases and controls in overweight or lean, obese, or nonobese subjects (data not shown).
###end p 33
###begin p 34
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 309 310 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 319 329 319 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4(a)</xref>
###xml 415 416 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 650 651 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 704 705 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 760 761 756 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 791 792 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 744 747 <span type="species:ncbi:9606">men</span>
###xml 773 778 <span type="species:ncbi:9606">women</span>
Pooled estimate of CHD odds ratios were calculated from published studies for the PPARG Ala12Pro SNP including 6898 cases and 11 287 controls. Funnel plot analysis revealed no evidence of publication bias. There was no significant association with CHD under the dominant genetic model (OR = 1.00 [0.93-1.08], P = .95) (Table 4(a)). There was significant heterogeneity in the meta-analysis (Chi(2) = 22.10, df = 13, P = .05) due to the study of Li et al., which was the only study to show a significant association between the Ala12 allele and a higher CHD risk. When removing this study from the meta-analysis (heterogeneity Chi(2) = 17.37, df = 12, P = .14), the odds ratio of CHD was 0.99 [0.92-1.07], P = .82. The ORs of CHD were similar in men (OR = 0.99, P = .91) and women (OR = 0.94, P = .52).
###end p 34
###begin p 35
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 147 157 147 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4(b)</xref>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 308 318 308 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4(c)</xref>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 197 200 <span type="species:ncbi:9606">men</span>
###xml 277 280 <span type="species:ncbi:9606">men</span>
###xml 362 367 <span type="species:ncbi:9606">women</span>
Using the recessive genetic model, there was a borderline association between the Ala12Ala genotype and CHD risk (OR = 1.29 [0.99-1.67], P = .06) (Table 4(b)). When stratifying on gender, Ala12Ala men had a significant higher risk of CHD (OR = 1.73 [1.20-2.48], P = .003) than men carrying the Pro12 allele (Table 4(c)). No such association could be detected in women (OR = 0.62 [0.31-1.24], P = .17) (data not shown).
###end p 35
###begin title 36
4. Discussion
###end title 36
###begin p 37
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 171 174 <span type="species:ncbi:9606">men</span>
###xml 182 187 <span type="species:ncbi:9606">women</span>
###xml 370 373 <span type="species:ncbi:9606">men</span>
###xml 619 622 <span type="species:ncbi:9606">men</span>
In the present study, we did not find any consistent association between the PPARG C-681G, C-689T, Pro12Ala, or C1431T SNPs or related haplotypes and CHD risk, neither in men nor in women, in the PRIME and ADVANCE studies. Furthermore, analyses stratified on overweight or obesity revealed no evidence that these PPARG variants influence CHD risk in overweight or obese men. These data do not support the hypothesis that PPARG C-681G, C-689T, Pro12Ala, and C1431T polymorphisms are major risk factors for CHD but does not rule out the possibility of an association of small magnitude, especially in homozygote Ala12Ala men.
###end p 37
###begin p 38
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
PPARG is a ligand-activated transcription factor playing an important role in adipocyte differentiation, glucose homeostasis, and several vascular processes. In vitro studies have shown that the PPARG Ala12 allele decreases PPARG activation of reporter genes (4) and the -681G and -689T alleles are associated with lower PPARG promoter activity [4, 6, 7] suggesting that carriers of these alleles might have a lower PPARG-mediated activation of target genes than noncarriers.
###end p 38
###begin p 39
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 456 461 456 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
Earlier clinical and epidemiological studies have assessed the relationship between variability at the PPARG gene loci and CHD risk. The results of these investigations have been inconsistent with some studies showing a reduced risk of coronary heart disease [9, 22], other studies an increased risk [25-29] and some others reporting no association [10, 23, 30-33]. In contrast, three studies showed less intima-media carotid thickening in carriers of the PPARG Ala12 allele suggesting a possible relation between this variant and sub-clinical atherosclerosis [34-36].
###end p 39
###begin p 40
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG </italic>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 157 160 <span type="species:ncbi:9606">men</span>
###xml 441 444 <span type="species:ncbi:9606">men</span>
We found no consistent association for none of the 4 PPARG SNPs (C-681G, C-689T, Pro12Ala, and C1431T) in PRIME and ADVANCE. Only in PRIME, we observed that men homozygotes for the minor allele of the C-689T, Pro12Ala, and C1431T SNPs had a higher risk of CHD than homozygotes for the frequent allele. This result was further confirmed in the meta-analysis including 3060 cases and 5032 controls that showed a higher risk of CHD in Ala12Ala men. Recent genome whole association studies failed to identify associations with PPARG SNPs [37-42]. Firstly, this might be explained by the gender-specific effect and the restrictive recessive genetic model of the PPARG association. Secondly, the 4 SNPs that were investigated in the present study may not be the culprit ones, but rather be in linkage disequilibrium with a causal mutation, resulting in a dilution of a possible association.
###end p 40
###begin p 41
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 943 948 943 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1073 1078 1073 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1000 1003 <span type="species:ncbi:9606">men</span>
PPARG SNPs may affect CHD risk through their association with cardiovascular risk factors. In the present study, we found no evidence for significant differences in major cardiovascular risk factors for example, body mass index, lipid levels, or history of diabetes, between carriers and noncarriers of the minor alleles. The only exception was a borderline association with systolic blood pressure level which was lower in PPARG-681G, -689T, and Ala12 carriers than in noncarriers in the PRIME study and could confer some protection against CHD. These findings are in agreement with other studies which showed lower levels of blood pressure or risk of hypertension in carriers of the minor allele of the PPARG Pro12Ala SNP [43-45]. However, these associations are inconsistent across studies as some also reported higher levels [46, 47] or not significantly different levels [48, 49] of blood pressure between carriers and noncarriers of the PPARG Ala12 allele. In this sample of apparently healthy men, the prevalence of hypertension was low (~18%) and the impact of the PPARG-681G, -689T, and Ala12 alleles on blood pressure was clinically limited.
###end p 41
###begin p 42
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 403 408 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
An earlier study has reported a significant higher risk of MI and fatal CHD in overweight but not in normal weight subjects [10] suggesting that the impact of PPARG genotype may differ according to body fat mass. In the present study, which has a similar number of cases and controls, we found no evidence for such a relationship, suggesting that obesity is not a determinant of the association between PPARG genetic variability and CHD.
###end p 42
###begin title 43
5. Conclusion
###end title 43
###begin p 44
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG </italic>
###xml 359 362 <span type="species:ncbi:9606">men</span>
In the present study, there was no major consistent association between the PPARG C-681G, C-689T, Pro12Ala, and C1431T genotypes or related haplotypes and CHD risk. When combining our data with previous cohort studies, focusing on the PPARG Pro12Ala SNP, we found a significant association between the homozygote Ala12Ala genotype and a higher risk of CHD in men. Further studies are needed to definitely conclude.
###end p 44
###begin title 45
 The PRIME Study Group
###end title 45
###begin p 46
The Strasbourg MONICA Project, Department of Epidemiology and Public Health, Faculty of Medicine, Strasbourg, France (D. Arveiler, B. Haas).
###end p 46
###begin p 47
The Toulouse MONICA Project, INSERM U558, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, Toulouse, France (J. Ferrieres, JB. Ruidavets).
###end p 47
###begin p 48
The Lille MONICA Project, INSERM U744, Pasteur Institute, Lille, France (P. Amouyel, M. Montaye).
###end p 48
###begin p 49
The Department of Epidemiology and Public Health, Queen's University, Belfast, Northern Ireland (A. Evans, J. Yarnell, F. Kee).
###end p 49
###begin p 50
The Department of Atherosclerosis, INSERM U545, Lille, France (G. Luc, JM. Bard).
###end p 50
###begin p 51
The Laboratory of Haematology, INSERM U626, La Timone Hospital, Marseilles, France (I. Juhan-Vague, Pierre Morange).
###end p 51
###begin p 52
The Laboratory of Endocrinology, INSERM U563, Toulouse, France (B. Perret).
###end p 52
###begin p 53
The Vitamin Research Unit, The University of Bern, Bern, Switzerland (F. Gey).
###end p 53
###begin p 54
The Trace Element Laboratory, Department of Medicine, Queen's University Belfast, Northern Ireland (Jayne Woodside, Ian Young).
###end p 54
###begin p 55
The DNA Bank, INSERM U525, Paris, France (F. Cambien).
###end p 55
###begin p 56
The Coordinating Center, INSERM U780 (ex-U258), Paris-Villejuif, France (P. Ducimetiere, A. Bingham).
###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin p 58
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Supplementary Table 1: Baseline characteristics of controls according to PPARG genotypes in the PRIME Study.
###end p 58
###begin p 59
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Supplementary Table 2: Baseline characteristics of white controls according to the PPARG C-689T genotype in the ADVANCE Study.
###end p 59
###begin p 60
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Supplementary Table 3: Baseline characteristics of white controls according to the PPARG C-681G genotype in the ADVANCE Study.
###end p 60
###begin p 61
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Supplementary Table 4: Baseline characteristics of white controls according to the PPARG Pro12Ala genotype in the ADVANCE Study.
###end p 61
###begin p 62
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Supplementary Table 5: Baseline characteristics of white controls according to the PPARG C1431T genotype in the ADVANCE Study.
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin title 64
Acknowledgments
###end title 64
###begin p 65
###xml 527 539 <span type="species:ncbi:9606">participants</span>
The authors thank the following organizations which allowed the recruitment of the PRIME subjects: the Health Screening Centers organized by the Social Security of Lille (Institut Pasteur), Strasbourg, Toulouse, and Tourcoing; Occupational Medicine Services of Haute-Garonne, the Urban Community of Strasbourg, the Association inter-entreprises des services medicaux du travail de Lille et environs; the Comite pour le developpement de la medecine du travail; and the Mutuelle Generale des PTT du Bas-Rhin. They also thank the participants in the ADVANCE study. The PRIME study was supported by unrestricted grants from Merck Sharp & Dohme-Chibret (France) and from the Department of Health and Social Service (Northern Ireland) and by The Fondation de France. The ADVANCE study was supported by a grant from the Donald W. Reynolds Foundation.
###end p 65
###begin article-title 66
###xml 22 27 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The many faces of PPARgamma
###end article-title 66
###begin article-title 67
From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
###end article-title 67
###begin article-title 68
PPARs in diseases: control mechanisms of inflammation
###end article-title 68
###begin article-title 69
###xml 31 36 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
A Pro12Ala substitution in PPARgamma2associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
###end article-title 69
###begin article-title 70
###xml 73 78 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 125 131 <span type="species:ncbi:9606">humans</span>
A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans
###end article-title 70
###begin article-title 71
###xml 60 65 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
A functional polymorphism in a STAT5B site of the human PPARgamma3 gene promoter affects height and lipid metabolism in a French population
###end article-title 71
###begin article-title 72
###xml 19 24 19 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population
###end article-title 72
###begin article-title 73
###xml 63 68 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 117 120 <span type="species:ncbi:9606">men</span>
###xml 125 130 <span type="species:ncbi:9606">women</span>
Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women
###end article-title 73
###begin article-title 74
Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction
###end article-title 74
###begin article-title 75
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 108 111 <span type="species:ncbi:9606">men</span>
###xml 116 121 <span type="species:ncbi:9606">women</span>
Peroxisome proliferator-activated receptor-gamma2P12A polymorphism and risk of coronary heart disease in US men and women
###end article-title 75
###begin article-title 76
The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland
###end article-title 76
###begin article-title 77
###xml 92 95 <span type="species:ncbi:9606">men</span>
Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the prospective epidemiological study of myocardial infarction (PRIME) study
###end article-title 77
###begin article-title 78
Recruitment in the coronary artery disease risk development in young adults (cardia) study
###end article-title 78
###begin article-title 79
###xml 11 15 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
Statin and beta-blocker therapy and the initial presentation of coronary heart disease
###end article-title 79
###begin article-title 80
Metabolic syndrome and early-onset coronary artery disease. is the whole greater than its parts?
###end article-title 80
###begin article-title 81
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease
###end article-title 81
###begin article-title 82
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study
###end article-title 82
###begin article-title 83
Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm
###end article-title 83
###begin article-title 84
The interaction of selection and linkage. I. General considerations; heterotic models
###end article-title 84
###begin article-title 85
Specific haplotypes of the P-selectin gene are associated with myocardial infarction
###end article-title 85
###begin article-title 86
A new algorithm for haplotype-based association analysis: the stochastic-EM algorithm
###end article-title 86
###begin article-title 87
Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a go-DARTS study
###end article-title 87
###begin article-title 88
Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland
###end article-title 88
###begin article-title 89
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy
###end article-title 89
###begin article-title 90
###xml 64 69 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction
###end article-title 90
###begin article-title 91
Association between Pro 12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population
###end article-title 91
###begin article-title 92
Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study
###end article-title 92
###begin article-title 93
PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes
###end article-title 93
###begin article-title 94
Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland
###end article-title 94
###begin article-title 95
Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses
###end article-title 95
###begin article-title 96
###xml 48 53 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects
###end article-title 96
###begin article-title 97
###xml 71 76 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus
###end article-title 97
###begin article-title 98
###xml 48 53 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese
###end article-title 98
###begin article-title 99
###xml 68 73 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis
###end article-title 99
###begin article-title 100
###xml 79 84 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis
###end article-title 100
###begin article-title 101
A common allele on chromosome 9 associated with coronary heart disease
###end article-title 101
###begin article-title 102
A common variant on chromosome 9p21 affects the risk of myocardial infarction
###end article-title 102
###begin article-title 103
Genomewide association analysis of coronary artery disease
###end article-title 103
###begin article-title 104
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
###end article-title 104
###begin article-title 105
New susceptibility locus for coronary artery disease on chromosome 3q22.3
###end article-title 105
###begin article-title 106
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease
###end article-title 106
###begin article-title 107
Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases
###end article-title 107
###begin article-title 108
Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertension
###end article-title 108
###begin article-title 109
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project
###end article-title 109
###begin article-title 110
###xml 57 62 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Effect of the peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds
###end article-title 110
###begin article-title 111
###xml 46 51 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The peroxisome poliferator-activated receptor-gamma2 Pro 12Ala variant: association with type 2 diabetes and trait differences
###end article-title 111
###begin article-title 112
###xml 87 92 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 167 170 <span type="species:ncbi:9606">men</span>
Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men
###end article-title 112
###begin article-title 113
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2
###end article-title 113
###begin p 114
Baseline characteristics of subjects with incident CHD (case) and CHD-free (control) subjects in PRIME and ADVANCE.
###end p 114
###begin p 115
###xml 52 53 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
Data are expressed as means +/- SD or percentages. *T-test for continuous variables and Chi-square test for categorical variables. NA: Not available. BP: blood pressure.
###end p 115
###begin p 116
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
PPARG genotype distributions among white CHD cases and CHD-free controls and ORs [95% CI] of CHD.
###end p 116
###begin p 117
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
*P value for a global test of significance. Model 1: crude OR. Model 2: OR adjusted for age, BMI, educational level, smoking status, physical activity, alcohol intake, history of diabetes, history of hypertension, and history of dyslipidemia.
###end p 117
###begin p 118
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
Estimate of PPARG haplotype frequencies in cases and controls.
###end p 118
###begin p 119
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Only haplotypes with a frequency >1% are displayed. 1 and 2 represent the frequent and minor alleles, respectively. P value is for the global effect (5 df).
###end p 119

